Upstream Bio Inc.
- Address
- 890 Winter Street Suite 20
Sponsor Overview
Specializations
Chronic Rhinosinusitis with Nasal Polyps
Clinical research in chronic rhinosinusitis with nasal polyps centers on improving control of nasal polyps and related upper-airway inflammation, with attention to symptom burden and endoscopic outcomes.
- Endoscopic nasal polyp score
- Nasal corticosteroid background therapy
- Upper airway inflammation
The sponsor is active in respiratory and inflammatory disease research with a focus on conditions affecting the nasal and sinus passages.
Severe Asthma
Studies in severe asthma examine disease control, asthma exacerbations, and long-term treatment tolerability in adults with persistent airway inflammation.
- Asthma exacerbation prevention
- Long-term safety
- Adult severe asthma
Research activity in this area reflects interest in difficult-to-control airway disease and outcomes relevant to ongoing respiratory management.
Chronic Obstructive Pulmonary Disease
Clinical trials in chronic obstructive pulmonary disease focus on reducing COPD exacerbations and improving overall disease control in adults with moderate-to-severe respiratory impairment.
- COPD exacerbations
- Moderate-to-severe COPD
- Airflow limitation
This area adds to the sponsor’s portfolio in chronic inflammatory and obstructive lung disorders.
Type 2 Inflammatory Airway Disease
The sponsor’s pipeline spans overlapping type 2 inflammatory airway conditions, including upper and lower respiratory tract disorders characterized by eosinophilic inflammation and recurrent symptoms.
- Eosinophilic airway inflammation
- Respiratory immunology
- Chronic inflammatory airway disorders
This research landscape connects asthma, COPD, and nasal polyposis within a shared therapeutic domain.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Verekitug (UPB-101) in Adults with Severe Asthma: A Phase 2 Randomized, Double-blind, Placebo-controlled Study |  Bulgaria Czechia Germany Italy Poland Spain | Not Recruiting |
| Efficacy and Safety Evaluation of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps on Nasal Corticosteroids: A Randomized, Double-Blind, Placebo-Controlled Study | Czechia Germany Poland Spain | Not Recruiting |
| Efficacy and Safety Evaluation of Verekitug (UPB-101) in Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study | Bulgaria Czechia Germany Hungary Ireland Latvia Lithuania Poland Romania Slovakia Spain | Not Recruiting |
| Long-Term Evaluation of Safety and Efficacy of Verekitug (UPB-101), a Human IgG1 Kappa Monoclonal Antibody Against CRLF2, in Adults with Severe Asthma | Bulgaria Czechia Germany Italy Poland Spain | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 158 sites across their trial portfolio.
Therapeutic Focus
- 1.Respiratory Tract Diseases4 trials277 other sponsors
Partnered Research Centres
158 centres- Address
- Bulevard Nikola Yonkov Vaptsarov 51b, 1407 Sofia
- Address
- Ul. Polskiego Czerwonego Krzyza 26, 33-100 Tarnow
- Address
- Al. Gen. Jozefa Hallera 95, 53-201 Wroclaw
- Address
- Ulitsa Chavdar Voyvoda 16, 7002 Rousse
- Address
- Romania, Strada Florilor 7, 077025 Bragadiru
- Address
- Bulevardul Ghencea 43b, 061692 Bucharest
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Upstream Bio Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.